{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:12:55Z","timestamp":1787800375812,"version":"build-2784847793"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although accumulating evidence suggests that inflammatory processes play a role in the pathophysiology of mental disorders, few studies have investigated this matter in panic disorder (PD). Furthermore, no studies to date have evaluated cytokine levels in drug-na\u00efve patients with PD. Therefore, little is known about the presence of inflammation at the onset of this disorder. The aim of the present study was to determine the levels of the proinflammatory interleukins IL-1B and IL-2R and the anti-inflammatory cytokine IL-10 in drug-na\u00efve PD patients. Analysis of serum chemokine levels revealed increased proinflammatory activity in the early phase of PD through increased IL-2R and IL-1B levels and a decrease in IL-10 levels in drug-na\u00efve PD patients compared to matched healthy controls. Neurotransmitters and neurocircuits that are targets of inflammatory responses are discussed, followed by an examination of brain\u2013immune interactions as risk factors for PD. This study is the first to identify a proinflammatory cytokine response in drug-na\u00efve PD subjects. These findings indicate that treatments targeting proinflammatory markers may ameliorate anxiety symptoms in PD patients.<\/jats:p>","DOI":"10.1038\/s41398-022-01835-y","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T18:03:05Z","timestamp":1645552985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cytokine profile in drug-na\u00efve panic disorder patients"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6928-5847","authenticated-orcid":false,"given":"Laiana A.","family":"Quagliato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2152-4669","authenticated-orcid":false,"given":"Antonio E.","family":"Nardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"key":"1835_CR1","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1001\/archpsyc.63.4.415","volume":"63","author":"RC Kessler","year":"2006","unstructured":"Kessler RC, Chiu TW, Jin R, Ruscio A, Sher K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the national comorbidity survey replication. Arch Gen Psychiatry. 2006;63:415.","journal-title":"Arch Gen Psychiatry"},{"key":"1835_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14740338.2018.1429403","volume":"17","author":"LA Quagliato","year":"2018","unstructured":"Quagliato LA, Freire RC, Nardi AE. Risks and benefits of medications for panic disorder: a comparison of SSRIs and benzodiazepines. Expert Opin Drug Saf. 2018;17:315\u2013324.","journal-title":"Expert Opin Drug Saf"},{"key":"1835_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1017\/S109285290000691X","volume":"8","author":"MH Pollack","year":"2003","unstructured":"Pollack MH, Allgulander C, Bandelow B, Cassano GB, Greist JH, Hollander E, et al. WCA recommendations for the long-term treatment of panic disorder. CNS Spectr. 2003;8:17\u201330.","journal-title":"CNS Spectr."},{"key":"1835_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jad.2017.11.094","volume":"228","author":"LA Quagliato","year":"2018","unstructured":"Quagliato LA, Nardi AE. Cytokine alterations in panic disorder: a systematic review. J Affect Disord 2018;228:91\u201396.","journal-title":"J Affect Disord"},{"key":"1835_CR5","doi-asserted-by":"publisher","unstructured":"Kettenmann, H, Kirchhoff, F, Verkhratsky, A microglia: new roles for the synaptic stripper. Neuron (2013). https:\/\/doi.org\/10.1016\/j.neuron.2012.12.023.","DOI":"10.1016\/j.neuron.2012.12.023"},{"key":"1835_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jpsychires.2019.03.027","volume":"113","author":"LA Quagliato","year":"2019","unstructured":"Quagliato LA, Freire RC, Nardi AE. Elevated peripheral kynurenine\/tryptophan ratio predicts poor short-term auditory memory in panic disorder patients. J Psychiatr Res. 2019;113:159\u2013164.","journal-title":"J Psychiatr Res."},{"key":"1835_CR7","doi-asserted-by":"publisher","first-page":"14817","DOI":"10.1073\/pnas.1009164107","volume":"107","author":"GM Slavich","year":"2010","unstructured":"Slavich GM, Way BM, Eisenberger NI, Taylor SE. Neural sensitivity to social rejection is associated with inflammatory responses to social stress. Proc Natl Acad Sci. 2010;107:14817\u201314822.","journal-title":"Proc Natl Acad Sci"},{"key":"1835_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.biopsych.2009.03.015","volume":"66","author":"NA Harrison","year":"2009","unstructured":"Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Critchley HD. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry. 2009;66:407\u2013414.","journal-title":"Biol Psychiatry"},{"key":"1835_CR9","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.tics.2004.05.010","volume":"8","author":"NI Eisenberger","year":"2004","unstructured":"Eisenberger NI, Lieberman MD. Why rejection hurts: a common neural alarm system for physical and social pain. Trends Cogn Sci. 2004;8:294\u2013300.","journal-title":"Trends Cogn Sci"},{"key":"1835_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"M Hamilton","year":"1959","unstructured":"Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50\u201355.","journal-title":"Br J Med Psychol"},{"key":"1835_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56\u201362.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1835_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/00004850-199506000-00003","volume":"10","author":"B Bandelow","year":"1995","unstructured":"Bandelow B. Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int Clin Psychopharmacol. 1995;10:73\u201382.","journal-title":"Int Clin Psychopharmacol"},{"key":"1835_CR13","doi-asserted-by":"publisher","unstructured":"Padhi A, Fineberg N Clinical Global Impression Scales. in Encyclopedia of Psychopharmacology. 303\u2013303 (Springer Berlin Heidelberg, 2010). https:\/\/doi.org\/10.1007\/978-3-540-68706-1_1422.","DOI":"10.1007\/978-3-540-68706-1_1422"},{"key":"1835_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.brainresbull.2011.10.004","volume":"87","author":"JA Smith","year":"2012","unstructured":"Smith JA, Das A, Ray SK, Banik NL. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull. 2012;87:10\u201320.","journal-title":"Brain Res Bull"},{"key":"1835_CR15","doi-asserted-by":"crossref","unstructured":"Dong R, Huang R, Wang J, Liu H, Xu Z. Effects of microglial activation and polarization on brain injury after stroke. Front Neurol. 2021;12:620948.","DOI":"10.3389\/fneur.2021.620948"},{"key":"1835_CR16","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1089\/ars.2017.7099","volume":"28","author":"G Aguilera","year":"2018","unstructured":"Aguilera G, Col\u00edn-Gonz\u00e1lez AL, Rangel-L\u00f3pez E, Chavarr\u00eda A, Santamar\u00eda A. Redox Signaling, Neuroinflammation, and Neurodegeneration. Antioxid Redox Signal. 2018;28:1626\u20131651.","journal-title":"Antioxid Redox Signal."},{"key":"1835_CR17","doi-asserted-by":"publisher","first-page":"602.","DOI":"10.3389\/fimmu.2015.00602","volume":"6","author":"TT Braga","year":"2015","unstructured":"Braga TT, Agudelo JSH, Camara NOS. Macrophages during the fibrotic process: M2 as friend and foe. Front Immunol. 2015;6:602.","journal-title":"Front Immunol"},{"key":"1835_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3389\/fnmol.2017.00421","volume":"10","author":"TL Tay","year":"2018","unstructured":"Tay TL, B\u00e9chade C, D'Andrea I, St-Pierre MK, Henry MS, Roumier A, et al. Microglia gone rogue: impacts on psychiatric disorders across the lifespan. Front Mol Neurosci. 2018;10:421\u2013432.","journal-title":"Front Mol Neurosci"},{"key":"1835_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/608654","volume":"2013","author":"LR Frick","year":"2013","unstructured":"Frick LR, Williams K, Pittenger C. Microglial dysregulation in psychiatric disease. Clin Dev Immunol 2013;2013:1\u201310.","journal-title":"Clin Dev Immunol"},{"key":"1835_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.neuroscience.2015.05.018","volume":"300","author":"GZ R\u00e9us","year":"2015","unstructured":"R\u00e9us GZ, Fries GR, Stertz L, Badawy M, Passos IC, Barichello T, et al. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience. 2015;300:141\u2013154.","journal-title":"Neuroscience"},{"key":"1835_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/npp.2011.205","volume":"37","author":"E Haroon","year":"2012","unstructured":"Haroon E, Raison CL, Miller AH. Psychoneuroimmunology Meets Neuropsychopharmacology: Translational Implications of the Impact of Inflammation on Behavior. Neuropsychopharmacology. 2012;37:137\u2013162.","journal-title":"Neuropsychopharmacology"},{"key":"1835_CR22","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1038\/npp.2010.116","volume":"35","author":"CB Zhu","year":"2010","unstructured":"Zhu CB, Lindler KM, Owens AW, Daws LC, Blakely RD, Hewlett WA. Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. Neuropsychopharmacology. 2010;35:2510\u20132520.","journal-title":"Neuropsychopharmacology"},{"key":"1835_CR23","doi-asserted-by":"publisher","first-page":"622","DOI":"10.2174\/138920008785821738","volume":"9","author":"GS Neurauter","year":"2008","unstructured":"Neurauter GS, Chr\u00f6cksnadel K, Scholl-B\u00fcrgi S, Sperner-Unterweger B, Schubert C, Ledochowski M, et al. Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr Drug Metab. 2008;9:622\u2013627.","journal-title":"Curr Drug Metab."},{"key":"1835_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bbi.2012.10.010","volume":"31","author":"JC Felger","year":"2013","unstructured":"Felger JC, Li L, Marvar PJ, Woolwine BJ, Harrison DG, Raison CL, et al. Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations. Brain Behav Immun. 2013;31:153\u2013160.","journal-title":"Brain Behav Immun."},{"key":"1835_CR25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.biopsych.2010.12.006","volume":"70","author":"L Capuron","year":"2011","unstructured":"Capuron L, Schr\u00f6cksnadel S, F\u00e9art C, Aubert A, Higueret D, Barberger-Gateau P, et al. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry. 2011;70:175\u201382.","journal-title":"Biol Psychiatry"},{"key":"1835_CR26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrn3257","volume":"13","author":"R Schwarcz","year":"2012","unstructured":"Schwarcz R, Bruno JP, Muchowski PJ, Wu H-Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012;13:465\u2013477.","journal-title":"Nat Rev Neurosci"},{"key":"1835_CR27","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0197-0186(01)00133-4","volume":"40","author":"RG Tavares","year":"2002","unstructured":"Tavares RG, Tasca CI, Santos CE, Alves LB, Porci\u00fancula LO, Emanuelli T, et al. Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem Int. 2002;40:621\u2013627.","journal-title":"Neurochem Int."},{"key":"1835_CR28","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1002\/jnr.21325","volume":"85","author":"S Tilleux","year":"2007","unstructured":"Tilleux S, Hermans E. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res. 2007;85:2059\u20132070.","journal-title":"J Neurosci Res."},{"key":"1835_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neuropharm.2015.10.034","volume":"102","author":"C Bj\u00f6rkholm","year":"2016","unstructured":"Bj\u00f6rkholm C, Monteggia LM. BDNF\u2014a key transducer of antidepressant effects. Neuropharmacology. 2016;102:72\u201379.","journal-title":"Neuropharmacology"},{"key":"1835_CR30","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1073\/pnas.0910658107","volume":"107","author":"JW Koo","year":"2010","unstructured":"Koo JW, Russo SJ, Ferguson D, Nestler EJ, Duman RS. Nuclear factor- B is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc Natl Acad Sci. 2010;107:2669\u20132674.","journal-title":"Proc Natl Acad Sci."},{"key":"1835_CR31","doi-asserted-by":"publisher","first-page":"5563","DOI":"10.2174\/1381612823666170809100230","volume":"23","author":"E Palma","year":"2018","unstructured":"Palma E, Ruffolo G, Cifelli P, Roseti C, Vliet EAV, Aronica E. Modulation of GABAA Receptors in the Treatment of Epilepsy. Curr Pharm Des. 2018;23:5563\u20135568.","journal-title":"Curr Pharm Des."},{"key":"1835_CR32","first-page":"167","volume":"30","author":"P Zwanzger","year":"2005","unstructured":"Zwanzger P, Rupprecht R. Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J Psychiatry Neurosci. 2005;30:167\u201375.","journal-title":"J Psychiatry Neurosci"},{"key":"1835_CR33","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/jcbfm.2009.240","volume":"30","author":"BD Semple","year":"2010","unstructured":"Semple BD, Kossmann T, Morganti-Kossmann MC. Role of chemokines in CNS health and pathology: a focus on the CCL2\/CCR2 and CXCL8\/CXCR2 networks. J Cereb Blood Flow Metab 2010;30:459\u2013473.","journal-title":"J Cereb Blood Flow Metab"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-01835-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-01835-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-01835-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T19:09:28Z","timestamp":1669230568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-01835-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1835"],"URL":"https:\/\/doi.org\/10.1038\/s41398-022-01835-y","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]},"assertion":[{"value":"23 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}